A series of cationic gold(I) heteroleptic complexes bearing the pyrazole-derived N-heterocyclic carbene (NHC) FPyr (1,2,3,4,6,7,8,9-octahydropyridazino[1,2-a]indazolin-11-ylidene), and either a 1,3-disubstituted benzimidazole-derived NHC of the type RR′-bimy (3: R = R′ = CHPh2; 4: R = CHPh2, R′ = iPr; 5: R = R′ = CH2Ph; 6: R = R′ = iBu; 7: R = R′ = n-Pr; 8: R = R′ = Et; 9: R = R′ = 2-propenyl) or a non-NHC co-ligand L (10: L = PPh3; 11: L = P(OPh)3; 12: L = DMAP) (DMAP = 4-dimethylaminopyridine) have been synthesized from [AuCl(FPyr)] (1). Complexes 3–12 have been characterized using multinuclei NMR spectroscopies, ESI mass spectrometry, and elemental analysis. X-ray diffraction analyses have been performed on complexes 5, 6, and 9–11. To the best of our knowledge, 11 represents the first gold–NHC complex to bear the P(OPh)3 ligand. The cytotoxic activities of complexes 3–12 have been studied in vitro with the NCI-H1666 non-small cell lung cancer cell line.
一系列阳离子
金(I)异
配体配合物,具有源自
吡唑的N-杂环卡宾(NHC) FPyr(1,2,3,4,6,7,8,9-八氢
吡唑啉[1,2-a]
茚唑啉-11-亚
氟),以及一种1,3-取代
苯并咪唑衍生的NHC(类型为RR′-bimy,如3:R = R′ = CHPh2;4:R = CHPh2,R′ = iPr;5:R = R′ = CH2Ph;6:R = R′ = iBu;7:R = R′ = n-Pr;8:R = R′ = Et;9:R = R′ = 2-
丙烯基)或非NHC协同
配体L(10:L = PPh3;11:L = P(OPh)3;12:L =
DMAP)(
DMAP = 4-二甲
氨基吡啶)已从[AuCl(FPyr)](1)合成。配合物3–12已通过多核NMR光谱、ESI质谱和元素分析进行表征。配合物5、6和9–11的X射线衍射分析已被执行。据我们所知,11是第一种具有P(OPh)3
配体的
金–NHC配合物。配合物3–12在体外使用NCI-H1666非小细胞肺癌
细胞系进行细胞毒性活性研究。